Sonus Complete - Is This Best Tinnitus Relief Formula That Works?
November 27, 2020 01:19 ET
|
Sonus Complete
New York City, NY, Nov. 27, 2020 (GLOBE NEWSWIRE) -- Different triggers expose you to depreciating health. Hearing is one of the senses that gets affected by various elements within and outside our...
CaptionCall Honors Military Veterans and Families for Their Service
November 11, 2020 08:11 ET
|
CaptionCall, LLC
SALT LAKE CITY, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Today, CaptionCall honors America’s military members, veterans, and their families who have answered the call to serve. Currently, there are about...
Otonomy Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 04, 2020 16:17 ET
|
Otonomy, Inc.
Enrollment completed in Phase 3 clinical trial of OTIVIDEX® in Ménière’s disease with results expected in the first quarter of 2021Positive results reported for Phase 1/2 clinical trial of OTO-313 in...
Otonomy to Report Third Quarter 2020 Financial Results and Provide Corporate Update
October 28, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Completes Patient Enrollment for Phase 3 Trial of OTIVIDEX® in Ménière’s Disease
October 02, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy to Participate in Four Upcoming Investor Conferences
September 02, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 04, 2020 16:22 ET
|
Otonomy, Inc.
Positive top-line results reported for Phase 1/2 trial of OTO-313 in tinnitus patientsPublic offering completed for total gross proceeds of $69.1 millionResults from Phase 3 trial of OTIVIDEX® in...
Otonomy Announces Exclusive License Agreement with Kyorin for Novel Compound in OTO-6XX Hearing Loss Program
August 03, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced an...
Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate Update
July 28, 2020 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 13, 2020 16:01 ET
|
Otonomy, Inc.
SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...